Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease.

Vernacchio, L; Neufeld, E J; MacDonald, K; Kurth, S; Murakami, S; Hohne, C; King, M; Molrine, D · J Pediatr · 1998

rct · Level II

Where this comes from

Abstract

We compared the immunogenicity of 7-valent pneumococcal-conjugate vaccine plus 23-valent pneumococcal vaccine to immunization with 23-valent vaccine only in individuals > or = 2 years of age with sickle cell disease. IgG pneumococcal antibody concentrations were higher in the combined schedule group with no increase in side effects observed after immunization with 23-valent vaccine.

Medical subject headings